EGFR and colorectal carcinoma: The potentiation in sensitivity to vemurafenib with the addition of a SRC inhibitor was conserved across various vemurafenib-resistant BRAFV600E CRC cell lines (HT29, KM20, LIM2405, LS411N, OUMS23, RKO1, SNUC5, VACO432, WiDr), as shown in Fig. 2b; the EGFR inhibitor gefitinib was included for comparison.